Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Hepatology. 2018 Sep 30;68(5):1905–1921. doi: 10.1002/hep.30061

Fig. 6. Hepatic Tregs upregulate the activation markers ICOS and CD39 upon treatment with IL-2c.

Fig. 6

Male Mdr2−/− and age- and gender-matched heterozygous mice were treated with i.p. IL-2c (or PBS in controls) twice weekly from day of life 14-30. Flow cytometric analysis of hepatic and splenic mononuclear cells identified the proportion of CD3+CD4+CD25+FoxP3(GFP)+ Tregs displaying surface expression of the activation marker ICOS (A), the suppressor molecule GITR (B), and the ectonucleotidase CD39 (C). Statistical significance between two groups was assessed with an unpaired t test with *p<0.05, **p<0.01, and ***p<0.005.